Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents
Graphical abstract
Section snippets
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgements
We acknowledge the principal financial supports from the National Foundation for Science and Technology of Vietnam (NAFOSTED, Grant number 104.01-2019.09). The work was also partly supported by a grant funded by the Korean Government (NRF-2017R1A5A2015541).
References (36)
- et al.
Epigenomes as therapeutic targets
Pharmacol Ther
(2015) - et al.
HDAC family: what are the cancer relevant targets?
Cancer Lett
(2009) HDAC inhibitors: Clinical update and mechanism-based potential
Biochem Pharmacol
(2007)- et al.
Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents
Bioorg Med Chem Lett
(2011) - et al.
Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents
Eur J Med Chem
(2013) - et al.
Novel 2-oxoindoline-based hydroxamic acids: synthesis, cytotoxicity, and inhibition of histone deacetylation
Tetrahedron Lett
(2015) - et al.
Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents
Bioorg Chem
(2018) - et al.
Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity
Bioorg Chem
(2017) - et al.
Synthesis of (E)-oxindolylidene acetate using tandem palladium-catalyzed Heck and alkoxycarbonylation reactions
Org Biomol Chem
(2016) - et al.
Design of tetrapeptide ligands as inhibitors of the Src SH2 domain
Bioorg Med Chem
(2004)
Histone deacetylases (HDACs): characterization of the classical HDAC family
Biochem J
(2003)
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
Biologics
(2012)
Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011–2013)
Expert Opin Ther Pat
(2014)
Histone deacetylase inhibitors: an attractive strategy for cancer therapy
Curr Med Chem
(2013)
Emerging approaches for histone deacetylase inhibitor drug discovery
Expert Opin Drug Discov
(2015)
New and emerging HDAC inhibitors for cancer treatment
J Clin Invest
(2014)
Anticancer activities of histone deacetylase inhibitors
Nat Rev Drug Discov
(2006)
Romidepsin for the treatment of peripheral T-Cell lymphoma
Oncologist
(2015)
Cited by (0)
© 2020 Elsevier Ltd. All rights reserved.